Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer

NCT00525759 is registered in ClinicalTrials.gov with Sheffield Teaching Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT00525759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00525759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer
Lead sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
January 31, 2010
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer